Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
08
09
2020
accepted:
30
01
2021
revised:
29
12
2020
pubmed:
23
2
2021
medline:
5
8
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
Post-traumatic stress disorder (PTSD) is difficult to treat but one promising strategy is to block memory reconsolidation of the traumatic event. This study aimed to evaluate the efficacy of traumatic memory reactivation under the influence of propranolol, a noradrenergic beta-receptor blocker, in reducing PTSD symptoms as well as comorbid major depression (MD) symptoms. We conducted a double blind, placebo-controlled, randomised clinical trial in 66 adults diagnosed with longstanding PTSD. Propranolol or a placebo was administered 90 min before a brief memory reactivation session, once a week for 6 consecutive weeks. Measures included the SCID PTSD module, the PTSD Check List (PCL-S) and the Beck Depression Inventory-II (BDI-II). PTSD symptoms decreased both in the pre-reactivation propranolol group (39.28%) and the pre-reactivation placebo group (34.48 %). During the 6 treatment sessions, PCL-S and BDI-II scores decreased to similar extent in both groups and there were no treatment differences. During the 3-month follow-up period, there were no treatment effects for the mean PCL-S and BDI-II scores. However, in patients with severe PTSD symptoms (PCL-S ≥ 65) before treatment, PCL-S and BDI-II scores continued to decline 3 months after the end of treatment in the propranolol group while they increased in the placebo group. Repeated traumatic memory reactivation seemed to be effective for PTSD and comorbid MD symptoms. However, the efficacy of propranolol was not greater than that of placebo 1 week post treatment. Furthermore, in this traumatic memory reactivation, PTSD symptom severity at baseline might have influenced the post-treatment effect of propranolol.
Identifiants
pubmed: 33612830
doi: 10.1038/s41386-021-00984-w
pii: 10.1038/s41386-021-00984-w
pmc: PMC7897457
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Propranolol
9Y8NXQ24VQ
Banques de données
ClinicalTrials.gov
['NCT01713556']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1643-1649Informations de copyright
© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
Yin Q, Sun Z, Liu T, Ni X, Deng X, Jia Y, et al. Posttraumatic stress symptoms of health care workers during the corona virus disease 2019. Clin. Psychol. Psychother. https://doi.org/10.1002/cpp.2477(2020) .
Guo Q, Zheng Y, Shi J, Wang J, Li G, Li C, et al., Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun. https://doi.org/10.1016/j.bbi.2020.05.038(2020) .
Tran K, Moulton K, Santesso N, Rabb D, CADTH Health Technology Assessments, Cognitive processing therapy for post-traumatic stress disorder: a systematic review and meta-analysis. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2016.
Kline AC, Cooper AA, Rytwinksi NK, Feeny NC. Long-term efficacy of psychotherapy for posttraumatic stress disorder: a meta-analysis of randomized controlled trials. Clin Psychol Rev. 2018;59:30–40.
doi: 10.1016/j.cpr.2017.10.009
Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol. 2012;15:825–40.
doi: 10.1017/S1461145711001209
Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs. 2004;64:383–404.
doi: 10.2165/00003495-200464040-00004
Krystal JH, Davis LL, Neylan TC, M AR, Schnurr PP, Stein MB, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD Psychopharmacology Working Group. Biol Psychiatry. 2017;82:e51–e59.
doi: 10.1016/j.biopsych.2017.03.007
Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories after their reactivation: role of beta adrenergic receptors. J Neurosci. 1999;19:6623–8.
doi: 10.1523/JNEUROSCI.19-15-06623.1999
Sara SJ. Retrieval and reconsolidation: toward a neurobiology of remembering. Learn Mem. 2000;7:73–84.
Nader K, Schafe GE, Le Doux JE. Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature. 2000;406:722–6.
doi: 10.1038/35021052
Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr SP, et al. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. J Clin Psychopharmacol. 2011;31:547–50.
doi: 10.1097/JCP.0b013e318222f360
Debiec J, Bush DE, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats-a possible mechanism for the persistence of traumatic memories in PTSD. Depression Anxiety. 2011;28:186–93.
doi: 10.1002/da.20803
Strawn JR, Geracioti TD Jr. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depression Anxiety. 2008;25:260–71.
doi: 10.1002/da.20292
Villain H, Benkahoul A, Drougard A, Lafragette M, Muzotte E, Pech S et al. Effects of propranolol, a beta-noradrenergic antagonist, on memory consolidation and reconsolidation in mice. Front Behav Neurosci. 2016;10:49.
doi: 10.3389/fnbeh.2016.00049
Kindt M, Soeter M, Vervliet B. Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci. 2009;12:256–8.
doi: 10.1038/nn.2271
Lonergan MH, Olivera-Figueroa LA, Pitman RK, Brunet A. Propranolol’s effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis. J psychiatry Neurosci. 2013;38:222–31.
doi: 10.1503/jpn.120111
Lonergan M, Saumier D, Tremblay J, Kieffer B, Brown TG, Brunet A. Reactivating addiction-related memories under propranolol to reduce craving: a pilot randomized controlled trial. J Behav Ther Exp Psychiatry. 2016;50:245–9.
doi: 10.1016/j.jbtep.2015.09.012
Soeter M, Kindt M. An abrupt transformation of phobic behavior after a post-retrieval amnesic agent. Biol Psychiatry. 2015;78:880–6.
doi: 10.1016/j.biopsych.2015.04.006
Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008;42:503–6.
doi: 10.1016/j.jpsychires.2007.05.006
Brunet A, Ashbaugh AR, Saumier D, Nelson M, Pitman RK, Tremblay J, et al. Does reconsolidation occur in humans: a reply. Front Behav Neurosci. 2011;5:74
doi: 10.3389/fnbeh.2011.00074
Wood NE, Rosasco ML, Suris AM, Spring JD, Marin MF, Lasko NB, et al. Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies. Psychiatry Res. 2015;225:31–39.
doi: 10.1016/j.psychres.2014.09.005
Brunet A, Saumier D, Liu A, Streiner DL, Tremblay J, Pitman RK. Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial. Am J Psychiatry. 2018;175:427–33.
doi: 10.1176/appi.ajp.2017.17050481
Estévez-Lamorte N, Pitzurra R, Foster S, Gmel G, Mohler-Kuo M, Schnyder U. Exposure to potentially traumatic events in young Swiss men: associations with socio-demographics and mental health outcomes (alcohol use disorder, major depression and suicide attempts). Eur J Psychotraumatol. 2019;10:1611093.
doi: 10.1080/20008198.2019.1611093
Elhai JD, Grubaugh AL, Kashdan TB, Frueh BC. Empirical examination of a proposed refinement to DSM-IV posttraumatic stress disorder symptom criteria using the National Comorbidity Survey Replication data. J Clin Psychiatry. 2008;69:597–602.
doi: 10.4088/JCP.v69n0411
El-Hage W, Birmes P, Jehel L, Ferreri F, Benoit M, Vidailhet P et al. Improving the mental health system for trauma victims in France. Eur J Psychotraumatol. 2019;10:1617610.
doi: 10.1080/20008198.2019.1617610
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV Axis I Disorders, research version, non-patient edition (SCID-I/NP). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 2002.
Ventureyra VA, Yao SN, Cottraux J, Note I, De Mey-Guillard C. The validation of the Posttraumatic Stress Disorder Checklist Scale in posttraumatic stress disorder and nonclinical subjects. Psychother Psychosom. 2002;71:47–53.
doi: 10.1159/000049343
First M, Spitzer R, Gibbon M. Structured clinical interview for DSMIV (Axis I Disorders): Nonpatient edition. New York, NY: Biometrics Research Department, NY State Psychiatric Institute; 1995.
Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Personal Assess. 1996;67:588–97.
doi: 10.1207/s15327752jpa6703_13
Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options, The. J Clin Psychiatry. 2002;63:826–37.
doi: 10.4088/JCP.v63n0913
Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Investig. 1980;65:338–46.
doi: 10.1172/JCI109677
Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Investig. 1980;65:338–46.
doi: 10.1172/JCI109677
Hoffman BB. Cathecolamines, sympathomimetic drugs and adrenergic receptor antagonists. In: Brunton L, editor. Goodman & Gilman’s: the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001, p. 215–68.
Dey M, Brisson J, Davis G, Enever R, Pray K, Zaim B, et al. Relationship between plasma propranolol concentration and dose in young, healthy volunteers. Biopharm Drug Dispos. 1986;7:103–11.
doi: 10.1002/bdd.2510070202
Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162:214–27.
doi: 10.1176/appi.ajp.162.2.214
Suzuki A, Josselyn SA, Frankland PW, Masushige S, Silva AJ, Kida S. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci. 2004;24:4787–95.
doi: 10.1523/JNEUROSCI.5491-03.2004
Roley ME, Claycomb MA, Contractor AA, Dranger P, Armour C, Elhai JD. The relationship between rumination, PTSD, and depression symptoms. J Affect Disord. 2015;180:116–21.
doi: 10.1016/j.jad.2015.04.006
Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12:467–77.
doi: 10.1038/nrn3027
Köhler CA, Carvalho AF, Alves GS, McIntyre RS, Hyphantis TN, Cammarota M. Autobiographical memory disturbances in depression: a novel therapeutic target? Neural Plast. 2015;2015:759139.
doi: 10.1155/2015/759139
Geracioti TD,Jr., Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001;158:1227–30.
doi: 10.1176/appi.ajp.158.8.1227
De Jaeger X, Courtey J, Brus M, Artinian J, Villain H, Bacquie E, et al. Characterization of spatial memory reconsolidation. Learn Mem. 2014;21:316–24.
doi: 10.1101/lm.033415.113